<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="174362">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00826020</url>
  </required_header>
  <id_info>
    <org_study_id>084-09-FB</org_study_id>
    <nct_id>NCT00826020</nct_id>
  </id_info>
  <brief_title>Evaluation of Omegaven™ Parenteral Nutrition in Patients With TPN-Induced Cholestasis</brief_title>
  <official_title>Prospective Evaluation of a Parenteral Omega-3 Fatty Acid Preparation (Omegaven™) in Therapy of Patients With TPN-Induced Cholestasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if established parenteral nutrition (PN)
      associated liver disease can be reversed or its progression halted by using a parenteral fat
      emulsion prepared from fish oil as measured by normalization of serum levels of hepatic
      enzymes and bilirubin.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression to small bowel transplantation.</measure>
    <time_frame>Bi-weekly x4, then monthly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if established PN associated liver disease can be reversed or its progression halted by using a fish oil parenteral emulsion as measured by normalization of serum levels of hepatic enzymes and bilirubin.</measure>
    <time_frame>weekly x 4, then bi-weekly x4, then monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Parenteral Nutrition Associated Liver Disease PNALD</condition>
  <condition>Cholestasis</condition>
  <arm_group>
    <arm_group_label>Omegaven™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omegaven™</intervention_name>
    <description>10% Omegaven™, 50 or 100 mL bottle; 1gram/kg/day and is infused over 12-24 hours.</description>
    <arm_group_label>Omegaven™</arm_group_label>
    <other_name>Omega-3 fat emulsion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be enrolled in the Intestinal Rehabilitation Program at the University
             of Nebraska Medical Center, AND:

          -  Be unable to meet nutritional needs solely by enteral nutrition and be expected to
             require PN for at least another 30 days

          -  Have clinical evidence of parenteral nutrition associated liver disease (PNALD) as
             defined as a direct bilirubin of 2 mg/dl or more. A liver biopsy is desirable but not
             necessary for treatment

          -  Signed patient informed consent

        Exclusion Criteria:

          -  Parent or guardian or child unwilling to provide consent or assent

          -  Inability or unwillingness on the part of parent/guardian or child to follow clinical
             recommendations of the Intestinal Rehabilitation Program

          -  Allergies or clinical conditions precluding safe use of Omegaven™
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David F Mercer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Alwayn IP, Gura K, Nosé V, Zausche B, Javid P, Garza J, Verbesey J, Voss S, Ollero M, Andersson C, Bistrian B, Folkman J, Puder M. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005 Mar;57(3):445-52. Epub 2005 Jan 19.</citation>
    <PMID>15659701</PMID>
  </reference>
  <reference>
    <citation>Van Aerde JE, Duerksen DR, Gramlich L, Meddings JB, Chan G, Thomson AB, Clandinin MT. Intravenous fish oil emulsion attenuates total parenteral nutrition-induced cholestasis in newborn piglets. Pediatr Res. 1999 Feb;45(2):202-8.</citation>
    <PMID>10022591</PMID>
  </reference>
  <reference>
    <citation>Gura KM, Parsons SK, Bechard LJ, Henderson T, Dorsey M, Phipatanakul W, Duggan C, Puder M, Lenders C. Use of a fish oil-based lipid emulsion to treat essential fatty acid deficiency in a soy allergic patient receiving parenteral nutrition. Clin Nutr. 2005 Oct;24(5):839-47.</citation>
    <PMID>16029913</PMID>
  </reference>
  <reference>
    <citation>Gura KM, Lee S, Valim C, Zhou J, Kim S, Modi BP, Arsenault DA, Strijbosch RA, Lopes S, Duggan C, Puder M. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics. 2008 Mar;121(3):e678-86. doi: 10.1542/peds.2007-2248.</citation>
    <PMID>18310188</PMID>
  </reference>
  <reference>
    <citation>Diamond IR, Sterescu A, Pencharz PB, Kim JH, Wales PW. Changing the paradigm: omegaven for the treatment of liver failure in pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr. 2009 Feb;48(2):209-15. doi: 10.1097/MPG.0b013e318182c8f6.</citation>
    <PMID>19179884</PMID>
  </reference>
  <verification_date>May 2009</verification_date>
  <lastchanged_date>May 4, 2009</lastchanged_date>
  <firstreceived_date>January 15, 2009</firstreceived_date>
  <responsible_party>
    <name_title>David Mercer, MD, PhD</name_title>
    <organization>University of Nebraska Medical Center</organization>
  </responsible_party>
  <keyword>PN</keyword>
  <keyword>parenteral nutrition</keyword>
  <keyword>fat emulsions</keyword>
  <keyword>omega-6 fatty acid</keyword>
  <keyword>liver disease</keyword>
  <keyword>fatty acid deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
